NCT06361888 2025-12-30
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Hutchmed
Phase 2/3 Recruiting
Hutchmed
Shanghai Zhongshan Hospital
Shanghai Zhongshan Hospital
Guangxi Medical University
RenJi Hospital